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Abstract
Background: For advanced pancreatic cancer, many regimens have been compared with gemcitabine (G) as the standard
arm in randomized controlled trials. Few regimens have been directly compared with each other in randomized controlled
trials and the relative efficacy and safety among them remains unclear.
Methods: A systematic review was performed through MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials,
and ASCO meeting abstracts up to May 2013 to identify randomized controlled trials that included advanced pancreatic
cancer comparing the following regimens: G, G+5-fluorouracil, G+ capecitabine, G+S1, G+ cisplatin, G+ oxaliplatin, G+
erlotinib, G+ nab-paclitaxel, and FOLFIRINOX. Overall survival and progression-free survival with 95% credible regions were
extracted using the Parmar method. A Bayesian multiple treatment comparisons was performed to compare all regimens
simultaneously.
Results: Twenty-two studies were identified and 16 were included in the meta-analysis. Median overall survival, progression
free survival, and response rates for G arms from all trials were similar, suggesting no significant clinical heterogeneity. For
overall survival, the mixed treatment comparisons found that the probability that FOLFIRINOX was the best regimen was
83%, while it was 11% for G+ nab-paclitaxel and 3% for G+ S1 and G+ erlotinib, respectively. The overall survival hazard ratio
for FOLFIRINOX versus G+ nab-paclitaxel was 0.79 [0.50–1.24], with no obvious difference in toxicities. The hazard ratios
from direct pairwise comparisons were consistent with the mixed treatment comparisons results.
Conclusions: FOLFIRINOX appeared to be the best regimen for advanced pancreatic cancer probabilistically, with a trend
towards improvement in survival when compared with other regimens by indirect comparisons.
Citation: Chan K, Shah K, Lien K, Coyle D, Lam H, et al. (2014) A Bayesian Meta-Analysis of Multiple Treatment Comparisons of Systemic Regimens for Advanced
Pancreatic Cancer. PLoS ONE 9(10): e108749. doi:10.1371/journal.pone.0108749
Editor: Jonathan R. Brody, Thomas Jefferson University, United States of America
Received July 15, 2014; Accepted August 25, 2014; Published October 6, 2014
Copyright:  2014 Chan et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Data Availability: The authors confirm that all data underlying the findings are fully available without restriction. All relevant data are within the paper and its
Supporting Information files.
Funding: The authors have no support or funding to report.
Competing Interests: Keya Shah has read the journal’s policy and the authors of this manuscript have the following competing interests: Yoo-Joung Ko
declared that he received research support and honoraria from Sanofi-Aventis, and Celgene; however, he has no stock ownership. The remaining authors have no
competing interests to declare. This does not alter the authors’ adherence to PLOS ONE policies on sharing data and materials.
* Email: kelvin.chan@sunnybrook.ca
Introduction
Pancreatic cancer is the 4th leading cause of cancer death in the
United States and 5th in the United Kingdom [1,2] with most
cases being categorized as either metastatic or locally advanced at
first presentation [3]. As potentially curative surgical resection can
be performed in only 15–20% of pancreatic cancer patients [4],
the treatment goal for the majority of these patients is palliative in
nature. For more than 15 years, the current standard of care for
advanced disease has been chemotherapy with gemcitabine alone
(G), after it was shown in a phase III randomized control trial
(RCT) to offer greater symptom relief with a modest 1-year
survival advantage (18% versus 2%) when compared to 5-
fluorouracil [5]. Since then, a number of phase II and III RCTs
have attempted to improve the gemcitabine anti-tumour activity
through gemcitabine-based combinations with cytotoxic and/or
targeted agents such as capecitabine, oxaliplatin, erlotinib, and
cisplatin [6–10]. Recent trials have also compared gemcitabine
alone to gemcitabine plus nab-paclitaxel (GnP), and a combination
regimen without gemcitabine consisting of folinic acid, fluoroura-
cil, irinotecan hydrochloride and oxaliplatin (FOLFIRINOX)
[11,12]. The trial of G versus GnP found statistically significant
hazard ratios (HRs) for overall survival (OS) in favour of the GnP
combination. The safety analysis found that serious life-threaten-
ing toxicity was not increased with GnP and that adverse events
were acceptable and manageable. Thus, the authors concluded
that GnP may be considered as a new standard of treatment for
advanced pancreatic cancer [11]. In the FOLFIRINOX trial,
survival was significantly better in the FOLFIRINOX group, but
with an increased occurrence of adverse events. The study
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concluded that FOLFIRINOX should also be considered as a
first-line option for advanced pancreatic cancer patients; however,
due to safety concerns, it should be reserved for patients younger
than 75 years of age and with a good performance status [12]. No
currently ongoing trials directly compare GnP and FOLFIRI-
NOX. While the addition of these two chemotherapy regimens
and their improvement in survival represent significant recent
progress over gemcitabine monotherapy, the most effective
chemotherapy strategy in clinical practice remains to be deter-
mined.
As direct comparison of combination therapies has been tested
mostly against single agent gemcitabine as the control arm in most
clinical trials, the relative effectiveness of the various regimens
remains unclear. In these instances, multiple treatment compar-
isons (MTC) can be used to synthesize evidence from RCTs using
both direct (head-to-head) and indirect (using a common
comparator) comparisons [13]. MTC are valuable tools that are
frequently employed by healthcare decision makers such as the
National Institute for Health and Clinical Excellence and the
Canadian Agency for Drugs and Technologies in Health, where
their usage is gaining widespread acceptance [14,15].
The aim of this study was to perform Bayesian MTC in order to
determine the most effective treatment for advanced pancreatic
cancer, taking into account the efficacy and safety profiles of each
regimen. Through our analysis, we were able to achieve this goal.
Methods
Literature Search
We conducted a systematic literature review through the
MEDLINE, EMBASE, and Cochrane Centre Register of Con-
trolled Trials databases, as well as ASCO meeting abstracts up to
and including May 23, 2013. Trials were limited to first-line
treatment in pancreatic cancer or adenocarcinoma patients.
Studies were limited to randomized controlled trials (RCTs) that
used one of the following chemotherapy regimens: G, G +
fluorouracil (GF), G + capecitabine (GCap), G + S1 (GS), G +
cisplatin (GCis), G + oxaliplatin (GOx), G + erlotinib (GE), GnP,
and FOLFIRINOX. These regimens were determined a priori by
the authors, as they are clinically the most commonly considered
treatments for advanced pancreatic cancer with prior studies
suggesting possible benefits to patients. The outcomes of interest
included OS, progression-free survival (PFS), and grade 3/4
toxicities. RCTs that did not include patients with advanced
pancreatic cancer were excluded. Non-randomized trials and
those concerning other malignancies, such as neuroendocrine
tumours or lymphoma, were excluded. Trials comparing radio-
therapy, hormonal, or gene therapy, and those comparing
chemotherapy to no treatment (best supportive care) were
excluded. No language restrictions were imposed. The articles
that were not freely available to us were requested from the
authors.
Screening
Two independent authors reviewed the literature search results
and included studies that met the prespecified eligibility criteria.
When reports overlapped or were duplicated, we retained the
study with the most recent data that could be used in the meta-
analysis. Discrepancies were resolved by consensus or by a third
author. Our review has been reported using the PRISMA
reporting guidelines (Checklist S1).
Data Abstraction and Analysis
Data recorded included the following: first author, publication
year, study location, regimens being compared, number of patients
randomized to each treatment arm, median age of patients,
percentage of patients with performance status of ECOG 0, 1, or 2
and the percentage of patients with locally advanced or advanced
disease respectively was recorded (Appendix S1 and S2). The
treatments were sorted into categories based on the regimen: G,
GF, GCap, GS, GCis, GOx, GE, GnP, and FOLFIRINOX. Risk
of bias assessment was performed using the Cochrane risk of bias
tool [16].
The data extracted from each study included the following: OS,
PFS, objective response rate (ObRR), and the occurrence of
adverse events (febrile neutropenia, neuropathy, fatigue, and
diarrhea) for all the chemotherapy regimens. If median values for
PFS and OS were available, they were also recorded. If the HRs
for OS and PFS were detailed in the publication, they were
extracted directly, along with 95% confidence intervals (CIs) from
Cox regression. Otherwise, HRs were calculated using the
methods outlined by Parmar et al [17]. A two-tailed p,0.05
value was recorded whenever available to determine whether a
statistically significant difference was detected between the two
regimens being compared. Two independent authors extracted
data and discrepancies were reviewed by a third author to reach
consensus.
Statistical Analysis
We first made pairwise comparisons of regimens from the trials
based on direct evidence only. We then performed MTC in a
Bayesian model. The MTC combined direct and indirect evidence
for specific pairwise comparisons and allowed data across a range
of regimens to be compared in a simple network. Bayesian
methods combine likelihoods, as a function of the parameters with
a prior probability distribution based on previous knowledge, to
obtain a posterior probability distribution of the parameters [18].
The posterior probabilities provide a straightforward way to
calculate the most effective treatment in the absence of head-to-
head trials. By plotting the posterior densities of the direct,
indirect, and network estimates, direct and indirect evidence can
be combined to provide a network estimate and a single effect size.
This effect size has increased precision than that of any one type of
evidence alone. The Bayesian approach has undergone significant
development in recent years and is able to monitor convergence in
posterior distribution and reflect the uncertainty in estimating
heterogeneity, offering significant improvements over the frequen-
tist random-effects model, which cannot estimate that uncertainty.
In more complex networks, especially those involving multi-armed
trials, Bayesian approaches are more developed and more
accessible than their frequentist counterparts [18,19].
Analyses were done using Bayesian Markov Chain Monte-Carlo
(MCMC) sampling in WinBUGS, version 1.4.3 and reported
according to the Quality of Reporting of Meta-analyses
(QUOROM) and International Society for Pharmacoeconomics
and Outcomes Research (ISPOR) guidelines. In WinBUGS, 3
chains were fit with 40,000 burn-ins and 40,000 iterations each.
Assessment of convergence was done using model diagnostics,
such as trace plots and the Brooks-Gelman-Rubin statistic [20].
Model fit was determined based on the residual deviance and
deviance information criterion (DIC) for each outcome measure.
The random effects model was used for OS, PFS, and ObRR
because the residual deviance was less than the number of
unconstrained data points and the deviance information criterion
for each of these outcome measures favoured this model over the
fixed effects model. Fixed effects were used in reporting toxicities
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because the residual deviance and DIC favoured this model. We
used the following non-informative prior distributions: uniform
(0,2) for standard deviation of the random effects model and
normal (0, tau = 0.0001) for log[HR]s. Non-informative priors
were used because this allowed the trial data to inform the results,
rather than letting strong priors dictate the results.
The primary endpoint was OS and the secondary endpoints
were PFS and ObRR. OS and PFS were summarized as log[HR],
ObRR and toxicities were summarized as log[Odds Ratio]. Effect
sizes are described with 95% credible regions (CRs), since
‘‘credible’’ is a more appropriate term than ‘‘confidence’’ when
conducting Bayesian MTC. Consistency between direct and
indirect evidence was assessed by comparing direct pairwise
comparison estimates to the results generated in the MTC.
Probability of each regimen being the best among all regimens
were computed by ranking the relative efficacies of all regimens in
each iteration and then calculating the proportion of each regimen
being ranked first across all iterations [21]. In order to assess the
comparability of included studies, between-study heterogeneity
was estimated and reported using the I2 statistic; the value of I2 lies
between 0% and 100%, where 0% indicates no observed
heterogeneity and larger values show increasing heterogeneity
[17].
Based on the HR results of the MTC, we attempted to project
the survival of patients receiving each of the regimens and
compared the results to the median OS of G. Projected median
OS was calculated using a median OS of 5.65 months for G as
reported by Buris et al [5]. Survival was estimated based on the
MTC results and the methods presented by Altman and Andersen
[22].
Results
Literature Search Results
Figure 1 shows a flow diagram of the selection process for the
studies included in our meta-analysis. 1269 studies were identified
from the literature search, 386 studies were excluded because they
were duplicates, and 801 were excluded after the abstracts were
reviewed based on the prespecified criteria. Of the 82 studies that
Figure 1. PRISMA Flow diagram of included and excluded trials identified from the literature search. There were 13 studies that were
excluded after full text review for ‘‘other’’ reasons. The reasons are as follows: 4 were secondary analyses, 2 were quality of life studies, 2 were pooled
analyses, 1 study was not randomized, 1 was a review, 1 was a tumour marker study, 1 was a safety analysis, and 1 study was excluded because it was
retrospective.
doi:10.1371/journal.pone.0108749.g001
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underwent full text review, 25 were excluded because they were an
abstract of a full-included study, 22 had a different comparison
arm, 4 were secondary analyses, 2 were quality of life studies, 2
were pooled analyses, 1 study was not randomized, 1 was a review,
1 was a tumour marker study, 1 was a safety analysis, and 1 study
was excluded because it was retrospective. Twenty-two studies
were identified to be included in this review [6–12,23–38]. 16
studies, involving 5488 randomized patients contained sufficient
data to be included in the quantitative synthesis (meta-analysis).
The studies included in the meta-analysis consisted of 15
manuscripts and 1 ASCO meeting abstract, which was subse-
quently published as a full manuscript [38]. The subsequent
publication was reviewed and the results were verified and found
to be identical to the results reported in the original abstract
[11,38].
Study Quality
A summary of the risk of bias for each included study can be
found in Appendices S14 and S15. All included studies were
randomized and 12 out of the 16 studies followed intention-to-
treat analysis for the primary endpoint, thus minimizing selection
bias and attrition bias, respectively. Only one study had blinding of
patients or personnel. Although blinding of outcome assessors was
not explicitly indicated, 13 studies had OS as the primary
endpoint, which would not be influenced by the outcome assessor.
Therefore there is a low risk of detection bias in these studies.
Allocation concealment was not mentioned in any of the studies,
so some potential selection bias may be present.
Trial Characteristics
The chemotherapy regimens used in the included studies were
G vs. GF (three studies), G vs. GCap (three studies), G vs. GS
(three studies), G vs. GCis (seven studies), G vs. GOx (two studies),
G vs. GE (one study), G vs. FOLFIRINOX (one study), GCap +
GOx (one study), and G + GnP (one study). The treatment
strategy network is shown in Figure 2. All trials included in the
meta-analysis reported median PFS and OS. There was no
significant clinical heterogeneity between the studies based on the
patient characteristics and outcomes in the G reference arm
(median PFS = 3 to 4 months, median OS =6 to 7 months)
(Appendix S3).
Comparison of Regimens
The outcomes assessed in all the trials were OS, PFS, ObRR,
and number of toxicity-related adverse events. Of the 16 trials that
compared different regimens, seven found statistically significant
differences in OS based on direct evidence only (Figure 3). These
seven studies compared G alone to a different treatment arm.
Direct comparisons detected statistically significant improvements
in OS with GnP versus G (HR =0.72, [95% CR 0.62–0.84]),
GCap versus G (HR =0.86, [0.75–0.98]), GE versus G (HR
=0.82, [0.69–0.97]), FOLFIRINOX versus G (HR =0.57, [0.45–
0.72]), GOx versus G (HR =0.87, [0.76–0.98]), and GS versus G
(HR =0.80, [0.66 to 0.96]). These results can be seen in Figure 3.
Statistical heterogeneity (I2.35%) was found only for the
comparisons of GCis versus G (seven studies, I2 = 64%) and GF
versus G (three studies, I2 = 62%) for OS. The direct comparisons
for PFS with I2 values are shown in Appendix S4.
Through our Bayesian MTC, HR comparisons were made of
OS (Figure 4) and PFS (Appendix S5) to compare all the regimens
simultaneously. The results of the MTC were similar to the results
seen in direct pairwise comparisons (Appendix S9). For OS, the
results of the Bayesian MTC found that the probability that
FOLFIRINOX was the best regimen was 83%, while it was 11%
for GnP and 3% for GS and GE, respectively. For PFS, the
Bayesian MTC found an 80% probability that FOLFIRINOX
was the best regimen. Figure 5 shows the probabilities of each
treatment regimen being the best in terms of OS. The probabilities
for PFS can be seen in Appendix S6.
The next best regimens according to the calculated probabilities
are GnP, GE, and GS. The OS HR for FOLFIRINOX versus GS
was 0.72 [0.48–1.11], FOLFIRINOX versus GnP was 0.79 [0.50–
1.24], and FOLFIRINOX versus GE was 0.70 [0.44–1.10], where
HRs are given with 95% CRs. The PFS HR for FOLFIRINOX
versus GS was 0.78 [0.47–1.40], FOLFIRINOX versus GnP was
0.68 [0.37–1.27], and FOLFIRINOX versus GE was 0.61 [0.33–
1.15].
Projected survivals were estimated comparing each regimen to
G. The projected median OS ranged from 5.8 months for GCis
and 9.9 months for FOLFIRINOX (see Table 1). The number
needed to treat (NNT) at 6 months and 1 year relative to G have
been shown in Table 1. The NNT at 1 year ranges from 5 for
FOLFIRINOX to 146 for GCis. These estimates will be helpful in
clinical decision-making and providing information to patients.
Odds ratio (OR) comparisons were made of ObRR (Appendix
S7) to compare all the regimens simultaneously. The Bayesian
MTC found a 58% probability that FOLFIRINOX is the best
regimen in terms of ObRR, while it was 33% and 8% for GnP and
GS respectively. The ObRR HR [95% CR] for FOLFIRINOX
versus GnP is 1.59 [0.74–2.94]. The probabilities that each
treatment regimen is the best in terms of ObRR are shown in
Appendix S8.
The toxicity-related adverse events assessed in this study were
febrile neutropenia and grade 3/4 fatigue, neuropathy, and
diarrhea, as these are the most clinically relevant treatment related
toxicities. ORs with 95% CRs were reported for each comparison
with sufficient direct evidence available to make network estimates
(Appendices S10, S11, S12, and S13). Based on cross-trial
comparisons, there was no obvious difference in toxicities for
Figure 2. Treatment strategy network. Numbers represent the
number of studies comparing the linked regimens; brackets represent
the number included in the quantitative analysis.
doi:10.1371/journal.pone.0108749.g002
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FOLFIRINOX and GnP. The raw numbers of toxicities from
each included study can be found in Appendix S3.
When comparing the direct pairwise comparisons to the results
generated from the MTC, we found that the results are consistent
(Appendix S9).
Discussion
Key Findings and Implications
Based on the analysis of both the direct evidence and MTC,
FOLFIRINOX had the highest probability of being the best
regimen in terms of both OS (83%) and PFS (80%). In our study,
selected comparisons of FOLFIRINOX with the regimens that
had the next highest probabilities were also conducted. These
results provide further evidence, albeit indirect, that FOLFIR-
INOX may be the most effective regimen in the treatment of
advanced pancreatic cancer. Although this meta-analysis allows
for network comparisons of FOLFIRINOX with other chemo-
therapy regimens, further large prospective trials with FOLFIR-
INOX and the other regimens, especially GnP, would ideally be
performed to confirm these results.
For over the past 15 years, gemcitabine monotherapy has been
the standard of care in many countries for the treatment of
metastatic pancreatic cancer based on its modest clinical efficacy.
Although the tumor response rate and survival benefit of
gemcitabine is modest, its favorable toxicity profile and ease of
administration has led to its wide spread and continued use. Many
studies have attempted to improve on the efficacy of gemcitabine
by adding either another chemotherapeutic agent or a targeted
agent. However, the vast majority of the phase III studies
conducted in this setting have been remarkably negative with
the exception of the addition of erlotinib and more recently, nab-
paclitaxel [38,39]. Although the gemcitabine and erlotinib study
demonstrated a statistically significant overall survival benefit in
favour of the combination, the modest improvement in survival
and higher toxicity likely influenced a more broad adoption of this
regimen.
In addition, a population-based study conducted in 2012
examined the tolerance and effectiveness of FOLFIRINOX at
three institutions [40]. The median PFS and OS reported in this
study were 7.5 and 13.5 months respectively [40]. The PFS and
OS from this study were actually higher than those from the
pivotal randomized trial by Conroy et al [12]. However, this may
be attributed to the fact that the population-based study included
patients with all stages of pancreatic cancer, while the Conroy
study enrolled only those with metastatic disease [12,40]. With
respect to adverse events, the observed rate of febrile neutropenia
in the population-based study was 4.9%, which is similar to the
rate observed in the Conroy study (5.4%), which suggests that the
results of the clinical trial may be generalizable to an uncontrolled
setting. This population-based study concluded that FOLFIR-
INOX was clinically effective in the treatment of advanced
pancreatic adenocarcinoma and that the toxicity profile of the
regimen does not outweigh the benefits in terms of ObRR and
Figure 3. Forest plot of direct comparisons between the regimens. Forest plot showing hazard ratio comparisons with 95% CI for overall
survival (OS) from meta-analyses of direct comparisons between different combinations of gemcitabine (GEM), gemcitabine + fluorouracil (GF),
gemcitabine + nab-paclitaxel (GnP), gemcitabine + capecitabine (GCap), gemcitabine + cisplatin (GCis), gemcitabine + erlotinib (GE), FOLFIRINOX,
gemcitabine + oxaliplatin (GOx), and G + S1 (GS). I2 values indicate statistical heterogeneity, where 0% indicates no observed heterogeneity and
larger values show increasing heterogeneity (17).
doi:10.1371/journal.pone.0108749.g003
Figure 4. Hazard ratio comparisons of overall survival (OS) from mixed treatment comparisons. Median values given with 95% credible
regions. Hazard ratios (HRs) expressed as experimental vs. control. G, gemcitabine; GF, gemcitabine + fluorouracil; GCap, gemcitabine + capecitabine;
GOx, gemcitabine + oxaliplatin; GCis, gemcitabine + cisplatin; FOLFIRINOX; GE, gemcitabine + erlotinib; GS, gemcitabine + S1; GnP, gemcitabine +
nab-paclitaxel.
doi:10.1371/journal.pone.0108749.g004
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survival [12,40]. Although FOLFIRINOX demonstrates the best
overall survival, progression-free survival, and objective response
rate as per the large Phase III Trial [12], it is important to note
that this regimen has a higher toxicity profile. When comparing
the safety profiles of FOLFIRINOX and GnP from two separate
clinical trials, the rate of febrile neutropenia in patients treated
with FOLFIRINOX was 5.4% [12], while it was 3% in the GnP
group [11]. G-CSF was administered in 42.5% of patients
receiving FOLFIRINOX [11] and in 26% of patients receiving
GnP [12]. In addition, it is important to note that the
FOLFIRINOX study excluded patients older than 75 years of
age and those with an ECOG performance status of 2. Therefore,
FOLFIRINOX may be more challenging to prescribe in elderly or
frail patients and caution should be taken in these cases. Ongoing
prospective population-based studies are being performed to assess
the efficacy and safety of FOLFIRINOX outside of clinical trials,
which will provide further real life experience of the regimen. In
addition, no population-based studies conducted to evaluate the
survival benefit and toxicity of GnP so further research should be
done in order to compare FOLFIRINOX with GnP in clinical
practice.
Strengths and Limitations
There are a number of strengths of the current MTC. For
example, a comprehensive and robust search strategy was used,
with data being extracted by two authors independently to ensure
accuracy. Although MTC allow indirect comparisons to be made,
these indirect estimates may be influenced by potential biases and
uncertainties. Multiple-treatment comparison meta-analysis
should be interpreted with caution and specifically, the underlying
assumptions of homogeneity and consistency of studies across the
network should be carefully scrutinized. In our study, heteroge-
neity between studies was indeed assessed and reported using I2
values. Although some heterogeneity was noted in the compari-
sons of GCis versus G and GF versus G, all studies in included in
the meta-analysis were comparable in terms of patient character-
istics and outcomes in the G reference arm (median PFS =3–4
months, median OS =6–7 months). The HRs from direct
pairwise comparisons and the MTC were also compared and
found to be consistent (Appendix S9). A limitation of our analysis
was the small number of studies included which is a reflection of
the landscape of the medical evidence. For many of the
comparisons, data was extracted from only one trial so any biases
or limitations from that study were more likely to affect the
conclusions drawn from the MTC. Another limitation of this
method is that it is based on published group data, rather than
individual patient information. Individual patient data may allow
for more patterns to be seen in terms of risk factors, however, it
would still remain difficult to make strong inferences in such a
complex network of treatments.
Both the FOLFIRINOX and nab-paclitaxel trials included only
those patients with metastatic pancreatic cancer in contrast to the
other gemcitabine combination studies, which enrolled both
metastatic and locally advanced pancreatic patients. One of the
Figure 5. Probabilities that each treatment regimen is the best
based on overall survival (OS). G, gemcitabine; GF, gemcitabine +
fluorouracil; GCap, gemcitabine + capecitabine; GOx, gemcitabine +
oxaliplatin; GCis, gemcitabine + cisplatin; FOLFIRINOX; GE, gemcitabine
+ erlotinib; GS, gemcitabine + S1; GnP, gemcitabine + nab-paclitaxel.
doi:10.1371/journal.pone.0108749.g005
Table 1. Comparisons of each regimen with Gemcitabine (G).
Regimen Name
OS Hazard Ratio when
compared with G
Projected Median OS
(months)*
NNT at 6 months when
compared with G
NNT at 1 year when compared
with G
FOLFIRINOX 0.57 9.9 6 5
G + nab-paclitaxel 0.72 7.8 9 9
G + S1 0.79 7.2 12 12
G + erlotinib 0.82 6.9 15 14
G + capecitabine 0.83 6.8 16 15
G + oxaliplatin 0.88 6.4 23 23
G + fluorouracil 0.94 6.0 46 47
G + cisplatin 0.98 5.8 141 146
G — 5.65 — —
Footnotes: Hazard ratios when comparing each regimen with Gemcitabine (G), projected median overall survival (OS), number needed to treat (NNT) at 6 months and 1
year when compared with G. Projected median OS was calculated using a median OS of 5.65 months as reported by Buris et al (5). Survival and NNT was estimated
based on the mixed treatment comparisons results and the method by Altman and Andersen (22).
doi:10.1371/journal.pone.0108749.t001
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reasons behind this shift in patient profile of advanced pancreatic
studies were the recommendations of a group of experts convened
in 2009 by the National Cancer Institute in the United States
based on the well described differences in survival between those
with locally advanced and metastatic disease. Unfortunately, this
difference in patient population across the trials included in our
study could not be accounted for. However, given that the
inclusion of locally advanced patients tends to magnify the overall
and progression free survival, we do not expect this difference in
the patients included in the studies to significantly influence our
observed results.
As RCTs directly comparing FOLFIRINOX and GnP, or other
existing regimens are unlikely to be conducted in advanced
pancreatic cancer in the future due to both commercial and
scientific reasons, indirect comparisons such as ours may represent
the best possible level of evidence as to which regimen is best. Such
indirect evidence may still in fact be informative in terms of both
clinical and policy decision-making.
Conclusions
Our meta-analysis reviewed and analyzed the existing high-
quality evidence for treating advanced pancreatic cancer in an
MTC, which help synthesize evidence and may inform decision-
making in the absence of direct pairwise comparisons. Based on
our MTC, FOLFIRINOX appears to be the most effective
regimen, however, direct pairwise comparisons are warranted to
definitively address. Existing uncertainties of the relative effective-
ness of FOLFIRINOX, as well as the potential toxicities and long-
term effects suggest that further clinical trials and longitudinal
studies are needed.
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